CACNA1H encodes Cav3.2, a low-voltage-activated (T-type) calcium channel alpha-1 pore-forming subunit that opens near resting membrane potentials and supports burst firing, rhythmicity, and rebound excitability in many neuronal populations.[1][2] Because Cav3.2 strongly shapes calcium entry during subthreshold activity, it sits at a critical interface between electrophysiology and stress pathways central to neurodegeneration.[2:1][3]
Cav3.2 channels are distinct from high-voltage-activated calcium channels in their activation range, inactivation kinetics, and recovery dynamics. In disease models, these properties can amplify aberrant oscillations, sleep-wake dysrhythmia, and pathological synchronization. Those network effects are directly relevant to symptom circuits in Parkinson's disease, Alzheimer's disease, and motor-system degeneration.[3:1][4]
| Property | Value |
|---|---|
| Protein | Cav3.2 (alpha-1H subunit) |
| Gene | CACNA1H |
| UniProt | O43497 |
| Family | T-type voltage-gated calcium channels (Cav3) |
| Core architecture | Four homologous domains, each with six transmembrane segments |
| Cellular location | Neuronal plasma membrane and excitable-cell membranes |
Cav3.2 contains the canonical voltage-gated calcium channel architecture (DI-DIV, each with S1-S6 segments and a pore loop), but its gating is tuned for low-threshold activation and rapid inactivation.[1:1][2:2] This enables Cav3.2 to:
Alternative splicing and post-translational regulation further diversify Cav3.2 behavior across circuits, meaning disease-relevant impact is often cell-state and circuit dependent rather than uniform across brain regions.[2:4][6]
Cav3.2 contributes to burst firing and oscillatory timing in thalamic and related relay networks. Dysregulated T-type signaling is linked to pathologic oscillation states and altered arousal architecture.[2:5][4:1]
In basal ganglia-thalamocortical circuits, altered low-threshold calcium conductance can promote abnormal rhythmicity that worsens motor control and may reinforce network-level dysfunction in Parkinson's disease.[3:2][4:2]
Cav3.2 is also important in peripheral and spinal excitability pathways, where it regulates sensory gain and excitability thresholds; these systems often overlap with non-motor symptom domains in neurodegenerative disease.[6:1][4:3]
Variants in CACNA1H are associated with channelopathy phenotypes, including epilepsy-spectrum disorders, providing clear human evidence that altered Cav3.2 function can drive clinically meaningful network dysfunction.[7][8]
Neurodegenerative disorders are strongly influenced by calcium stress, mitochondrial burden, and excitotoxic coupling. Cav3.2 can feed each of these processes by modulating repetitive calcium entry near threshold voltages, especially in metabolically vulnerable neurons.[3:3][4:4]
T-type channel inhibition has been explored as a strategy to normalize pathological firing dynamics. While not a disease-modifying solution by itself, Cav3.2 modulation is a plausible adjunct strategy in multimodal neuroprotection frameworks.[3:4][4:5]
These priorities align with broader mechanisms summarized in Calcium Channel Dysfunction in Neurodegeneration and Selective Neuronal Vulnerability.[3:5][4:6]
The study of Cacna1H Protein (Cav3.2 T Type Calcium Channel) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiological Reviews. 2003. ↩︎ ↩︎
Cain SM, Snutch TP. T-type calcium channels in burst-firing, rhythmicity, and disease. Channels. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacological Reviews. 2023. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Catterall WA. Voltage-gated calcium channels. Cold Spring Harbor Perspectives in Biology. 2011. ↩︎
Jagodic MM, Pathirathna S, Nelson MT, et al. Cell-specific alterations of T-type calcium currents in pain pathways. PNAS. 2007. ↩︎ ↩︎
Chen Y, Lu J, Pan H, et al. Association of CACNA1H variants with childhood absence epilepsy. Annals of Neurology. 2003. ↩︎
Chourasia N, et al. Functional consequences of CACNA1H channel variants in epilepsy phenotypes. Human Mutation. 2014. ↩︎